Astrazeneca Ab v. Mylan Pharmaceuticals Inc.

Procedural entryThis page is a short order in Astrazeneca Ab v. Mylan Pharmaceuticals Inc.. Read the opinion of the Court — 19 F.4th 1325
Court of Appeals for the Federal Circuit·Decided March 7, 2023·No. 23-1267·Unpublished

Opinion

Case: 23-1267 Document: 63 Page: 1 Filed: 03/07/2023

NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

ASTRAZENECA AB, ASTRAZENECA PHARMACEUTICALS LP, Plaintiffs-Appellees

v.

MYLAN PHARMACEUTICALS INC., KINDEVA DRUG DELIVERY L.P., Defendants-Appellants ______________________

2023-1267 ______________________

Appeal from the United States District Court for the Northern District of West Virginia in No. 1:22-cv-00035- JPB-RWT, Judge John Preston Bailey. ______________________

ON MOTION ______________________

PER CURIAM. ORDER The parties jointly move to remand the above-cap- tioned appeal with each side to bear its own costs and fees. Upon consideration thereof, IT IS ORDERED THAT: Case: 23-1267 Document: 63 Page: 2 Filed: 03/07/2023

The motion is granted.

FOR THE COURT

March 7, 2023 /s/ Peter R. Marksteiner Date Peter R. Marksteiner Clerk of Court

ISSUED AS A MANDATE: March 7, 2023

Free access — add to your briefcase to read the full text and ask questions with AI

Astrazeneca Ab v. Mylan Pharmaceuticals Inc., (Fed. Cir. 2023).

Astrazeneca Ab v. Mylan Pharmaceuticals Inc. (Astrazeneca Ab v. Mylan Pharmaceuticals Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.